

<i>Honoraret til valgkomiteen og kompensasjonskomiteen for perioden fra den ordinære generalforsamlingen i 2025 til den ordinære generalforsamlingen i 2026 fastsettes til:</i> <i>Leder i valgkomiteen NOK 30 000</i> <i>Medlem i valgkomiteen NOK 25 000</i> <i>Kompensasjonskomiteen NOK 25 000"</i>	<i>The remuneration to the Election Committee and the Remuneration Committee for the period from the ordinary general meeting in 2025 and to the annual general meeting in 2026 shall be:</i> <i>Chairman of the Committee NOK 30,000</i> <i>Members of the Committee NOK 25,000</i> <i>Remuneration Committee NOK 25,000"</i>
6. Honorar til revisor	6. Auditor's remuneration
Følgende vedtak ble fattet: <i>"Generalforsamlingen godkjenner revisors honorar for revisjonen av årsregnskapet til Vistin Pharma ASA for 2024 etter regning."</i>	The following resolution was passed: <i>"The general meeting approves the auditor's remuneration for audit of the Annual Financial Statements of Vistin Pharma ASA for the financial year of 2024 in accordance with invoice."</i>
7. Styrets erklæring om fastsettelse av lønn og annen godtgjørelse til ledende ansatte	7. The Board's statement regarding determination of salary and other compensation to leading employees
Styrets erklæring om lederlønsfastsettelse i henhold til allmennaksjeloven § 6-16a & b og tilhørende forskrift; en rapport om lønn og annen godtgjørelse til ledende personer, ble gjennomgått. Følgende vedtak ble fattet: Del 1: <i>"Generalforsamlingen gir sin tilslutning til styrets erklæring om lønn og annen godtgjørelse til ledende ansatte."</i> Del 2: <i>"Generalforsamlingen godkjenner styrets erklæring om langsiktige insentiv ordninger."</i>	The Board's statement on compensation to leading employees in accordance with the Norwegian Public Limited Companies Act ("the Act") section 6-16a & b and associated regulations; a report on remuneration to leading employees was discussed. The following resolution was passed: Part 1: <i>"The General Meeting supports the statement of the Board regarding compensation to leading employees."</i> Part 2: <i>"The General Meeting adopts the statement of the Board regarding long term incentive plans."</i>
8. Godkjenning av finansieringsbistand til ledende ansatte ifm. kjøp av aksjer i selskapet under langsiktig insentivavtale.	8. Approval of financial assistance to purchase shares in relation to the company's long-term incentive plan.
Styrets erklæring og redegjørelse, som var vedlagt innkallingen, i forbindelse med finansieringsbistand for kjøp av aksjer i selskapet til ledende ansatte ble gjennomgått. Følgende vedtak ble fattet: <i>"Generalforsamlingen godkjenner at selskapet stiller en låneramme på NOK 5 000 000 tilgjengelig for selskapets ledende ansatte. Lånerammen har en varighet på tre år, og kan kun benyttes til finansiering av aksjekjøp i selskapet."</i>	The statement and declaration prepared by the Board, which was attached to the notice, in relation to financial assistance to purchase shares in the company was discussed. The following resolution was passed: <i>"The General meeting approved a loan facility of NOK 5 000 000 to the executive management. The loan facility has a duration of three years and can only be used as financing for purchasing of shares in the company."</i>
9. Valg av medlemmer til styret	9. Election of members to the board of directors
Valgkomiteen har mottatt en forespørsel fra Øystein Stray Spetalen om at han ikke ønsker gjenvalg som styremedlem i Vistin Pharma ASA. Valgkomiteens konklusjon er at Øystein Spetalen ikke foreslås erstattet med et nytt styremedlem og at styret dermed reduseres med ett styremedlem.	<i>The Election Committee has received a request from Øystein Stray Spetalen that he does not want to be re-elected as a board member of Vistin Pharma ASA. The Election Committee's conclusion is that Øystein Spetalen is not proposed to be replaced with a new board member and that the board is thereby reduced by one board member.</i>

Følgende vedtak ble fattet: <i>"Innstillingen fra valgkomiteen om å gjenvelge Øystein Stray Spetalen som styremedlem ble derfor trukket."</i> Styret består da av følgende aksjonærvalgte og ansatte valgte medlemmer: • Øyvin A. Brøymer (Styreleder) • Bettina Banoun • Kari Krogstad • Espen Marcussen • Espen Lia Gregoriussen (ansatte representant) • Stine Wang Rønningen (ansatte representant) • Kjell-Erik Nordby (observatør)"	The following resolution was passed: <i>"The recommendation from the Election committee to re-elect Øystein Stray Spetalen as a Board member was therefore withdrawn."</i> The Board consists of the following shareholder and employee elected members: • Øyvin A. Brøymer (Chairman) • Bettina Banoun • Kari Krogstad • Espen Marcussen • Espen Lia Gregoriussen (employee representative) • Stine Wang Rønningen (employee representative) • Kjell-Erik Nordby (observer)"
10. Valg av medlemmer til valgkomiteen	10. Election of members to the nomination committee
Følgende vedtak ble fattet: <i>"Følgende velges som medlemmer av valgkomiteen for en periode på 2 (to) år, frem til den ordinære generalforsamling 2027:</i> • Eivind Devold (leder) • Nils Erling Ødegaard	The following resolution was passed: <i>"The Election Committee proposes that the following are elected as members of the board of directors for a period of 2 (two) years, until the annual general meeting 2027:</i> • Eivind Devold (Chairman) • Nils Erling Ødegaard
11. Valg av revisor	11. Election of Auditor
Følgende vedtak ble truffet: <i>"Generalforsamlingen godkjenner at EY fortsetter som revisor for Vistin Pharma ASA"</i>	The following resolution was passed: <i>"The General Meeting approves that EY will continue as auditor for Vistin Pharma ASA"</i>
12. Fullmakt til å utstede aksjer	12. Authorization to issue shares
Følgende vedtak ble truffet: <i>"Styret gis fullmakt til å øke aksjekapitalen med inntil NOK 8 868 918 gjennom én eller flere aksjekapitalutvidelser.</i> <i>Fullmakten skal kunne anvendes for følgende formål:</i> (i) <i>for å gi Selskapet finansiell fleksibilitet, herunder ved investeringer, oppkjøp og fusjoner.</i> <i>Pris og tegningsvilkår fastsettes av styret ved hver utstedelse under hensyn til Selskapets behov og aksjenes markedsverdi på det aktuelle tidspunkt. Aksjer vil kunne utstedes mot kontantvederlag eller vederlag i form av andre aktiva (tingsinnskudd).</i> <i>Eksisterende aksjonærs fortrinnsrett til å tegne aksjer vil kunne bli fraveket av styret i forbindelse med utøvelse av fullmakten.</i> <i>Denne fullmakt utløper på datoen for den ordinære generalforsamlingen i 2026, men skal i alle tilfelle utløpe senest 15 måneder fra datoen for denne generalforsamlingen.</i> <i>Styret gis samtidig fullmakt til å foreta nødvendige vedtektsendringer ved utøvelse av fullmakten."</i>	The following resolution was passed: <i>"The Board is granted authorization to increase the share capital with up to NOK 8 868 918, through one or several share capital increases.</i> <i>The authorization may be used for one or more of the following purposes:</i> (i) <i>to provide the Company with financial flexibility, including in connection with investments, mergers and acquisitions.</i> <i>Price and conditions for subscription will be determined by the Board on issuance, according to the Company's needs and the shares' market value at the time. Shares may be issued in exchange for cash settlement or contribution in kind.</i> <i>The existing shareholders pre-emptive rights to subscribe shares can be deviated from in connection with the effectuation of this authorization.</i> <i>The Board's authorization is valid until the Annual General Meeting in 2026, but shall in any event expire at the latest 15 months from the date of this annual general meeting.</i> <i>The Board is at the same time given authorization to make the necessary amendments to the articles of association on execution of the authorization."</i>

13. Fullmakt til å erverve egne aksjer	13. Authorization to acquire treasury shares
Følgende vedtak ble fattet: <i>"Styret gis fullmakt til på Selskapets vegne å erverve aksjer i Vistin Pharma ASA til ett eller flere av følgende formål:</i> (i) <i>for å øke aksjonærenes avkastning.</i> <i>Fullmakten gjelder for kjøp av inntil 10 % av pålydende av Selskapets aksjekapital, jf. allmennaksjeloven §§ 9-2 og 9-3. Aksjer kan erverves til minst NOK 1 per aksje og maksimalt NOK 100 per aksje. Disse begrensninger skal justeres tilsvarende i tilfelle av aksjespleis, aksjesplitt og lignende transaksjoner. Aksjene skal erverves ved ordinær omsetning over børs.</i> <i>Styrets fullmakt gjelder frem til den ordinære generalforsamlingen i 2026, men skal i alle tilfelle utløpe senest 15 måneder fra datoen for denne generalforsamlingen. Beslutningen skal meldes til og registreres av Foretaksregisteret innen aksjer erverves i henhold til fullmakten."</i>	The following resolution was passed: <i>"The Board is granted authorization to acquire shares in Vistin Pharma ASA on behalf of the Company for one or more of the following purposes:</i> (i) <i>to increase return on investment for the Company's shareholders.</i> <i>The authorization covers purchase(s) of up to 10% of the face value of the share capital of the Company, cf. the public limited liability companies act §§ 9-2 and 9-3. Shares may be acquired at minimum NOK 1 per share and maximum NOK 100 per share. These limitations shall be adjusted in the event of share consolidation, share splits, and similar transactions. The shares shall be acquired through ordinary purchase on the stock exchange. The Board's authorization is valid until the annual general meeting in 2026, but shall in any event expire at the latest 15 months from the date of this General Meeting. The decision shall be notified to and registered by the Norwegian Register of Business Enterprises prior to acquiring any shares pursuant to this authorization."</i>
Da det ikke forelå flere saker til behandling, takket møteleder for oppmøtet, og møtet ble hevet.	As there were no further matters on the agenda, the Chairman thanked the present shareholders for their participation, and the meeting was adjourned.
Vedlagt følger en detaljert oversikt over utfallet av avstemningene, herunder blant annet antall stemmer for og mot de respektive beslutningene, jf allmennaksjeloven § 5-16.	Attached is a detailed overview of the results and voting, including the number of votes for and against the respective resolutions, cf the Norwegian public limited companies act section 5-16.
*****	*****
Signatur følger på neste side.	The signature follows on the next page.

* These minutes are prepared in Norwegian, with an English office translation. In case of discrepancies between the two versions, the Norwegian version shall prevail.

Signature page for Vistin Pharma ASA Annual General Meeting 2025

Oslo, 22. Mai, 2025/ Oslo, May 22nd, 2025

Øyvind A. Brøymer

Sign.

Magnus W. Tolleshaug

Sign.

Total Represented

ISIN:	N00010734122 VISTIN PHARMA ASA
General meeting date:	22/05/2025 13.00
Today:	22.05.2025

Number of persons with voting rights represented/attended : 2

	Number of shares	% sc
Total shares	44,344,592	
- own shares of the company	0	
Total shares with voting rights	44,344,592	
Represented by own shares	14,509,280	32.72 %
Represented by advance vote	1,788,960	4.03 %
Sum own shares	16,298,240	36.75 %
Represented by proxy	5,156,012	11.63 %
Represented by voting instruction	2,991,773	6.75 %
Sum proxy shares	8,147,785	18.37 %
Total represented with voting rights	24,446,025	55.13 %
Total represented by share capital	24,446,025	55.13 %

Registrar for the company:	Signature company:
NORDEA BANK ABP, FILIAL NORGE	VISTIN PHARMA ASA

--	--

Protocol for general meeting VISTIN PHARMA ASA

ISIN: NO0010734122 VISTIN PHARMA ASA
 General meeting date: 22/05/2025 13.00
 Today: 22.05.2025

Shares class	For	Against	Poll in	Abstain	Poll not registered	Represented shares with voting rights
Agenda item 2 Election of the chairman of the meeting and a person to co-sign the minutes						
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %	
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 3 Approval of the notice of the meeting and the agenda						
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %	
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 4 Approval of the annual financial statements and the Directors report for 2024						
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %	
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 5 Approval of remuneration for the Board of Directors, the Election Committee and the Remuneration Committee						
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %	
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 6 Approval of auditors remuneration						
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %	
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 7.1 The General Meeting supports the statement of the Board regarding compensation to leading employees						
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %	
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 7.2 The General Meeting adopts the statement of the Board regarding long term incentive plans and measures for keeping key personnel						
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %	
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 8 Approval of financial assistance to purchase shares in relation to the company's long-term incentive plan.						
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %	
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 9 Election of members to the Board of Directors						
Ordinær	24,376,919	69,106	24,446,025	0	0	24,446,025
votes cast in %	99.72 %	0.28 %		0.00 %		
representation of sc in %	99.72 %	0.28 %	100.00 %	0.00 %	0.00 %	
total sc in %	54.97 %	0.16 %	55.13 %	0.00 %	0.00 %	

Shares class	For	Against	Poll in	Abstain	Poll not registered	Represented shares with voting rights
Total	24,376,919	69,106	24,446,025	0	0	24,446,025
Agenda item 10 Election of members to the Election Committee						
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %	
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 11 Election of Auditor						
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %	
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 12 Authorisation to issue shares						
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %	
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 13 Authorisation to acquire treasury shares						
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %	
Total	24,446,025	0	24,446,025	0	0	24,446,025

Registrar for the company:

NORDEA BANK ABP, FILIAL NORGE

Signature company:

VISTIN PHARMA ASA

Share information

Name	Total number of shares	Nominal value	Share capital	Voting rights
Ordinær	44,344,592	1.00	44,344,592.00	Yes
Sum:				

§ 5-17 Generally majority requirement

requires majority of the given votes

§ 5-18 Amendment to resolution

Requires two-thirds majority of the given votes

like the issued share capital represented/attended on the general meeting